Together these findings demonstrate that the combination of CQ and SAHA enhances endogenous thyroidal NIS expression and function in vivo, highlighting the potential of pharmacologically inhibiting NIS endocytosis to increase therapeutic radionuclide uptake in patients with thyroid cancer. This evidence concerns the gene SLC5A5 and thyroid gland carcinoma.